Showing results (231-240 of 249) with videos related to

Sort By:
Pageof 25
Ophthalmology|August 1, 1984
Malignant syringoma of the eyelidH J Glatt, A D Proia, E A Tsoy, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|April 24, 2010
Outcome and predictors of treatment failure in early post-surgical prosthetic joint infections due to Staphylococcus aureus treated with debridementF Vilchez, J C Martínez-Pastor, S García-Ramiro, et al.
The Journal of Cell Biology|December 1, 1992
Bilateral retinal and brain tumors in transgenic mice expressing simian virus 40 large T antigen under control of the human interphotoreceptor retinoid-binding protein promoterM R al-Ubaidi, R L Font, A B Quiambao, et al.
Neuroscience|May 27, 2009
Effects of the adenosine A 2A antagonist KW 6002 (istradefylline) on pimozide-induced oral tremor and striatal c-Fos expression: comparisons with the muscarinic antagonist tropicamideA J Betz, R Vontell, J Valenta, et al.
Science (New York, N.Y.)|April 22, 2006
Differential targeting of Gbetagamma-subunit signaling with small moleculesTabetha M Bonacci, Jennifer L Mathews, Chujun Yuan, et al.
American Journal of Ophthalmology|March 15, 1993
Pathologic features and immunofluorescent antibody demonstration of ocular microsporidiosis (Encephalitozoon hellem) in seven patients with acquired immunodeficiency syndromeD A Schwartz, G S Visvesvara, M C Diesenhouse, et al.
Investigative Ophthalmology & Visual Science|February 1, 1996
Trilateral tumors in four different lines of transgenic mice expressing SV40 T-antigenD M Marcus, J G Lasudry, J L Carpenter, et al.
Haematologica|December 10, 1999
Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology GroupA F Remacha, B Arrizabalaga, A Villegas, et al.
Clinical Epigenetics|January 15, 2021
Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survivalM Cabezón, R Malinverni, J Bargay, et al.
Leukemia|November 11, 2005
Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]G Perea, A Lasa, A Aventín, et al.
Pageof 25